1. Home
  2. SUPN vs POWI Comparison

SUPN vs POWI Comparison

Compare SUPN & POWI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • POWI
  • Stock Information
  • Founded
  • SUPN 2005
  • POWI 1988
  • Country
  • SUPN United States
  • POWI United States
  • Employees
  • SUPN N/A
  • POWI N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • POWI Semiconductors
  • Sector
  • SUPN Health Care
  • POWI Technology
  • Exchange
  • SUPN Nasdaq
  • POWI Nasdaq
  • Market Cap
  • SUPN 2.6B
  • POWI 2.6B
  • IPO Year
  • SUPN 2012
  • POWI 1997
  • Fundamental
  • Price
  • SUPN $44.80
  • POWI $44.59
  • Analyst Decision
  • SUPN Buy
  • POWI Strong Buy
  • Analyst Count
  • SUPN 2
  • POWI 3
  • Target Price
  • SUPN $43.00
  • POWI $61.67
  • AVG Volume (30 Days)
  • SUPN 654.2K
  • POWI 541.1K
  • Earning Date
  • SUPN 11-03-2025
  • POWI 11-05-2025
  • Dividend Yield
  • SUPN N/A
  • POWI 1.88%
  • EPS Growth
  • SUPN 1411.53
  • POWI N/A
  • EPS
  • SUPN 1.14
  • POWI 0.59
  • Revenue
  • SUPN $665,125,000.00
  • POWI $442,468,000.00
  • Revenue This Year
  • SUPN $4.84
  • POWI $11.06
  • Revenue Next Year
  • SUPN $17.69
  • POWI $14.36
  • P/E Ratio
  • SUPN $38.93
  • POWI $75.65
  • Revenue Growth
  • SUPN 5.55
  • POWI 7.16
  • 52 Week Low
  • SUPN $29.16
  • POWI $39.53
  • 52 Week High
  • SUPN $46.79
  • POWI $69.53
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 58.16
  • POWI 42.89
  • Support Level
  • SUPN $43.44
  • POWI $43.96
  • Resistance Level
  • SUPN $46.72
  • POWI $45.69
  • Average True Range (ATR)
  • SUPN 1.08
  • POWI 1.31
  • MACD
  • SUPN -0.48
  • POWI 0.21
  • Stochastic Oscillator
  • SUPN 40.60
  • POWI 41.50

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About POWI Power Integrations Inc.

Power Integrations Inc designs, develops, and markets analog and mixed-signal integrated circuits (ICs) and other electronic components and circuitry used in high-voltage power conversion. Products are used in power converters that convert electricity from a high-voltage source to the type of power required for a specified downstream use. Products are used in electronic products including mobile phones, computing and networking equipment, appliances, electronic utility meters, battery-powered tools, industrial controls, home automation, or Internet of Things applications such as networked thermostats, power strips, and security devices. Geographically, the company generates maximum revenue from China and Hong Kong.

Share on Social Networks: